⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
TAK News
Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)
2026 ASCO Abstract Highlights: Innovent Biologics' IBI363 (PD-1/IL-2α-bias bispecific fusion protein) Demonstrates Robust Survival Benefits in Long-Term Follow-up of PoC Study in Advanced Immunotherapy-Resistant Non-Small Cell Lung Cancer
prnewswire.com
TAK
Cutaneous T-Cell Lymphoma Clinical Trial Pipeline Accelerates as 30+ Pharma Companies Rigorously Developing Drugs for Market Entry | DelveInsight
globenewswire.com
SNGX
IPHA
BMY
NKTX
AZN
MRK
TAK
NVS
GMAB
ABBV
BIIB
CRSP
INCY
ALKS
PFE
REGN
GILD
AMGN
Attorneys at Hagens Berman Announce $474M Win in Amitiza Jury Trial Against Takeda
businesswire.com
TAK
Takeda Announces FY2025 Full Year Results and FY2026 Outlook, Highlighted by Excellent Pipeline Progress and Solid FY2025 Results
businesswire.com
TAK
武田薬品、原発性免疫不全症（PID）を対象としたTAK-881の主要第2/3相臨床試験で良好なトップライン結果を発表
businesswire.com
TAK
Community Servings' AMPL Institute Releases National Food is Medicine Report on Access to Medically Tailored Nutrition in the U.S.
prnewswire.com
TAK
Takeda presenta resultados positivos preliminares del ensayo pivotal de fase 2/3 de TAK-881 en inmunodeficiencia primaria (IDP)
businesswire.com
TAK
Takeda anuncia resultados positivos de primeira linha do estudo clínico pivotal de Fase 2/3 do TAK-881 em Imunodeficiência Primária (IDP)
businesswire.com
TAK
Takeda anuncia resultados positivos de primeira linha do estudo clínico pivotal de Fase 2/3 do TAK-881 em Imunodeficiência Primária (IDP)
businesswire.com
TAK
Riassunto: Takeda annuncia i risultati principali positivi dallo studio clinico pivotale di fase 2/3 su TAK-881 nella malattia da immunodeficienza primaria (IDP)
businesswire.com
TAK